Latest news
BioMarin: Amicus Integration Targets $280 Million Of Cost Cuts As Acquired Therapies Aim For 60%+ Operating Margin - Pulse 2.0Pulse 2.0 · Sat, 08 Aug 2026 02:37:10 GMTBlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 14:42:32 GMT